Barclays Downgrades Sanofi-Aventis (SNY) to Equalweight
Tweet Send to a FriendGet Alerts SNY Hot Sheet
Price: $53.84 --0%
Rating Summary:
7 Buy, 3 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Rating Summary:
7 Buy, 3 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Trade SNY Now!
Barclays downgraded Sanofi-Aventis (NYSE: SNY) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Sanofi-Aventis click here. For more ratings news on Sanofi-Aventis click here.
Shares of Sanofi-Aventis closed at $48.92 yesterday, with a 52 week range of $33.03-$49.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Sanofi-Aventis click here. For more ratings news on Sanofi-Aventis click here.
Shares of Sanofi-Aventis closed at $48.92 yesterday, with a 52 week range of $33.03-$49.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
- Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria
Create E-mail Alert Related Categories
DowngradesRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
